SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Dated: November 10, 2004
Commission File Number 001-32295
ADHEREX TECHNOLOGIES INC.
(Translation of registrants name into English)
2300 Englert Drive, Suite G
Research Triangle Park
Durham North Carolina 27713
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b)(7): ¨
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ¨ No x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82 - .
Adherex Technologies Inc.
On November 10, 2004, the Company issued a press release announcing that its Registration Statement on Form 20-F has been declared effective by the Securities and Exchange Commission and that the Companys application to list its common stock on the American Stock Exchange has been approved, pending continued compliance with applicable listing requirements on the date it begins trading on the Exchange. The press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ADHEREX TECHNOLOGIES INC.
Date November 10, 2004
By: /s/ James A. Klein, Jr.
James A. Klein, Jr.
Chief Financial Officer
|99.1||The Registrations Press Release dated November 10, 2004|
[ADHEREX LOGO APPEARS HERE]
ADHEREX RECEIVES APPROVAL FOR AMEX LISTING
- Trading expected to begin November 12, 2004 under the symbol ADH -
Research Triangle Park, NC, November 10, 2004Adherex Technologies Inc. (TSX: AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that the Companys Registration Statement on Form 20-F has been declared effective by the U.S. Securities and Exchange Commission (SEC) and that its application to list its shares on the American Stock Exchange (AMEX) has been approved. The Company anticipates that trading on the AMEX will begin at 9:30 a.m. on Friday, November 12, 2004, under the symbol ADH, pending continued compliance with all listing requirements on that date. Adherexs common stock will continue to trade on the Toronto Stock Exchange under the symbol AHX.
This listing is yet another milestone in Adherexs continued strategic growth and again delivers on our commitments to investors. A US listing provides access to a much broader investment base and should better position us for future initiatives, including partnering discussions, said William P. Peters, MD, PhD, Chairman and CEO of Adherex. Recognizing that clinical results build the true value in the Company, we remain focused on the continued development of our platform. Earlier this week, we presented additional clinical data that Exherin continues to be generally well tolerated and has shown important evidence of molecularly targeted anti-tumor activity in three patients, including an objective partial response, in our ongoing Phase I trial. It is this type of progress that we look forward to continuing to share with our current and future shareholders.
The AMEX approval is contingent upon Adherex being in compliance with all applicable listing standards on the date it begins trading on the American Stock Exchange, expected as of this Friday, and may be rescinded if the Company is not in compliance with such standards.
About Adherex Technologies
Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics to address unmet medical needs. Adherex currently has four products in the clinical stage of development including Exherin and sodium thiosulfate (STS). Exherin is being developed as an angiolytic that selectively targets established blood vessels that feed solid tumors. STS is being developed as an otoprotectant against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. Adherex is pioneering oncology company with a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics. For more information, please visit Adherexs website at www.adherex.com.
Certain statements contained in this press release are forward-looking and are subject to unknown risks and uncertainties. The actual results, performance or achievements of the Company may differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those relating to (i) the date that we anticipate trading to commence on AMEX and (ii) the continued progress in the development of our product candidates. The AMEX approval is contingent upon Adherex being in compliance with all applicable listing standards on the date it begins trading on the American Stock Exchange, and may be rescinded if the Company is not in compliance with such standards. We can provide no assurance that we will complete our planned product development on schedule, or at all, or that the results and data from such trials will be positive or consistent.
For further information, please contact:
|Director, Corporate Communications|
|Adherex Technologies Inc.|
|T: (919) 484-8484|
In the U.S.
Mark Vincent/ Brian Ritchie
|Euro RSCG Life NRP||NATIONAL ir|
|T : (212) 845-4200||T: (416) 586-0180|